查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018666

寡核苷酸合成市场：2026-2032年全球市场预测（按产品类型、合成规模、交货方式、应用和最终用户划分）

Oligonucleotide Synthesis Market by Product Type, Synthesis Scale, Delivery Method, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，寡核苷酸合成市场价值将达到 102.8 亿美元，到 2026 年将成长至 120.2 亿美元，到 2032 年将达到 316.9 亿美元，复合年增长率为 17.43%。

主要市场统计数据
基准年 2025 102.8亿美元
预计年份：2026年 120.2亿美元
预测年份 2032 316.9亿美元
复合年增长率 (%) 17.43%

透过对产业驱动因素和新兴技术创新的深入了解，我们将探索寡核苷酸合成不断扩展的前沿领域。

寡核苷酸合成处于分子层级创新与商业性机会的交会点。随着研究应用从精准诊断扩展到新一代疗法，支持寡核苷酸生产的製程和技术也迅速发展。本报告的引言部分追溯了该领域的发展历程，从早期的手工合成到如今的自动化高通量平台，说明了其背后的发展背景。

重新定义寡核苷酸生产的引入模式和技术突破：揭示关键的变革因素。

寡核苷酸合成领域正经历一场变革性的转变，其意义远不止于效能的渐进式提升。酶促方法的突破性进展正在重新定义效率，使得以前所未有的精度组装更长的链成为可能。同时，微阵列合成仪也从小众研究设备转变为主流工具，为高密度寡核苷酸库的广泛应用提供了可能。

评估 2025 年美国关税对寡核苷酸供应链、成本结构和市场动态的累积影响。

美国将于2025年实施新的关税，增加了全球寡核苷酸供应链的复杂性。对合成试剂、专用设备和客製化服务征收的额外关税，实际上提高了下游应用的采购成本。为此，製造商和终端用户正在重新审视筹资策略，探索在免税地区采购的替代方案，并考虑建立区域伙伴关係以减轻关税负担。

本分析全面检视了寡核苷酸市场的产品规模、交付方式、应用和最终用户等市场细分，并得出策略见解。

对于寻求优化策略定位的相关人员，对市场区隔的多方面理解至关重要。就产品类型而言，仪器和设备日趋成熟，DNA/RNA合成仪可为研究工作流程提供精确的输出，而微阵列平台则可同时合成数千种独特的序列。试剂和耗材构成另一个重要支柱，涵盖从酵素混合物和标记剂到纯化化合物的各个方面。同时，软体和服务正成为不可或缺的驱动力，生物资讯套件、基于云端的管理解决方案和数据分析平台可将原始序列数据转化为可操作的洞察。此外，合成寡核苷酸（无论是DNA还是RNA）正在推动诊断、治疗和其他领域的应用，凸显了高纯度最终产品的重要性。

阐明美洲、欧洲、中东和非洲以及亚太地区寡核苷酸合成市场的区域趋势。

区域趋势持续重塑寡核苷酸合成领域的竞争格局。在美洲，先进的研究基础设施、监管协调以及活跃的创业投资共同推动强劲的创新。从北美生物技术丛集到南美新兴中心，各机构都在增加整合设计、合成和下游应用的一体化平台的投资。

分析构成寡核苷酸合成生态系统的主要企业的竞争策略和创新者

寡核苷酸合成领域的竞争格局复杂，既有成熟的跨国公司，也有灵活的专业公司和新兴的生物技术企业。业界领导企业利用雄厚的研发预算，不断强化仪器设备，拓展试剂产品线，并整合先进的软体功能。这些投入使他们能够为高通量筛检和精准治疗设计提供端到端的解决方案。

促进寡核苷酸产业创新合作与韧性以实现永续成长的实用建议。

为了维持产业相关人员，应优先考虑贯穿整个合成价值链的协同创新。在仪器製造商、试剂供应商和终端用户之间建立开放式创新伙伴关係，能够将突破性的实验室成果快速转化为可扩展的製程流程。这使得企业可以共用资源、分担风险，并共同开发针对新兴应用（例如 RNA 疗法和照护现场诊断）的解决方案。

结合一级和二级分析的严格调查方法的详细信息，以确保在寡核苷酸研究中获得扎实的知识。

本分析基于一个综合研究框架，该框架结合了对各领域专家的初步研究以及来自同行评审学术期刊、专利资料库和监管出版刊物的二手资料分析。初步研究包括对主要仪器製造商、试剂製造商、受託研究机构和终端用户机构的高阶主管、研发经理和供应链经理进行深度访谈。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：寡核苷酸合成市场：依产品类型划分

  • 设备/器材
    • DNA/RNA合成器
    • 微阵列合成系统
  • 试剂和耗材
    • 酵素
    • 标记试剂
    • 纯化试剂
    • 合成试剂
  • 软体服务
    • 生物资讯学工具
    • 云端储存和管理解决方案
    • 客製化寡核苷酸合成服务
    • 数据分析平台
  • 合成寡核苷酸
    • DNA寡核苷酸
    • RNA寡核苷酸

第九章：依合成规模分類的二核苷酸合成市场

  • 客製化寡核苷酸合成
  • 大规模/商业化生产

第十章 寡核苷酸合成市场：依递送方式划分

  • 酵素合成
  • 固相合成

第十一章：寡核苷酸合成市场：依应用领域划分

  • 诊断
    • 生物感测器
    • 分子影像
    • PCR和定序
  • 药物发现与开发
    • 先导药物最适化
    • 目标检验
  • 研究
    • 功能基因体学
    • 基因表现分析
    • 基因合成
  • 治疗药物
    • 反义疗法
    • 基于CRISPR的疗法
    • RNA干扰

第十二章 寡核苷酸合成市场：依最终用户划分

  • 学术和研究机构
  • 合约研究机构
  • 诊断检测实验室
  • 製药和生物技术公司

第十三章 寡核苷酸合成市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 寡核苷酸合成市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 寡核苷酸合成市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国寡核苷酸合成市场

第十七章：中国寡核苷酸合成市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Bio-synthesis Inc.
  • Biocomma Ltd.
  • Biolegio BV
  • Biolytic Lab Performance Inc.
  • Bon Opus Biosciences, LLC
  • Creative Biogene
  • Cusabio Technology LLC
  • Danaher Corporation
  • Eurofins Genomics LLC
  • Eurogentec SA by Kaneka Corporation
  • GE HealthCare Technologies Inc.
  • Generi Biotech
  • Genscript Corporation
  • Hongene Biotech Corp.
  • LGC Genomics Limited
  • Maravai Intermediate Holdings, LLC
  • Merck KGaA
  • Microsynth AG
  • Nitto Denko Avecia Inc.
  • Novartis AG
  • parent added
  • PerkinElmer, Inc.
  • REPROCELL Inc.
  • Synbio Technologies
  • TAG Copenhagen A/S
  • TCI Chemicals（India）Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-0A609A26A918

The Oligonucleotide Synthesis Market was valued at USD 10.28 billion in 2025 and is projected to grow to USD 12.02 billion in 2026, with a CAGR of 17.43%, reaching USD 31.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.28 billion
Estimated Year [2026] USD 12.02 billion
Forecast Year [2032] USD 31.69 billion
CAGR (%) 17.43%

Navigating the Expanding Frontiers of Oligonucleotide Synthesis with Insights into Industry Drivers and Emerging Technological Innovations

Oligonucleotide synthesis stands at the nexus of molecular innovation and commercial opportunity. As research applications expand from precision diagnostics to next-generation therapeutics, the processes and technologies underpinning oligonucleotide production have evolved rapidly. This report's introduction sets the stage by tracing the field's growth from early manual syntheses to today's automated, high-throughput platforms.

In recent years, heightened demand for custom DNA and RNA fragments has catalyzed advancements across the supply chain, from novel enzymatic pathways to sophisticated cloud-based bioinformatics. Concurrently, the integration of microarray synthesizers with real-time quality control has unlocked new capabilities in genomic profiling and personalized medicine. These technological leaps have been accompanied by shifts in stakeholder expectations, requiring manufacturers to deliver both speed and precision at scale.

Against this backdrop, our exploration begins with an overview of the regulatory, economic, and technological drivers that underpin current and future developments. By contextualizing the synthesis landscape within broader industry imperatives-such as data security, reproducibility, and cost optimization-we provide decision-makers with a clear line of sight on the challenges and opportunities ahead.

Through this foundational lens, readers will gain an appreciation for how incremental innovations converge to reshape end-to-end workflows, ultimately fostering a more agile, responsive, and quality-driven market environment.

Unveiling the Key Transformative Forces Redefining Oligonucleotide Production Adoption Patterns and Technological Breakthroughs

The oligonucleotide synthesis sector is experiencing transformative shifts that extend well beyond incremental performance gains. Breakthroughs in enzymatic methodologies are redefining efficiency, enabling the assembly of longer strands with unprecedented fidelity. At the same time, microarray synthesizers have transitioned from niche research instruments to mainstream tools that democratize access to high-density oligo libraries.

From an operational perspective, the advent of cloud-enabled design and data management platforms has bolstered collaboration across geographically dispersed research teams. These platforms facilitate seamless integration of bioinformatics tools with synthesis workflows, accelerating the translation of digital sequence data into physical molecules. Meanwhile, the rise of custom synthesis services has fragmented the traditional vendor landscape, empowering end-users to specify highly tailored delivery timelines and purity standards.

In parallel, the convergence of automation and artificial intelligence is driving smarter quality control processes, reducing error rates, and minimizing waste. Predictive analytics now play a critical role in optimizing reagent consumption and scheduling maintenance, thereby lowering total cost of ownership. Moreover, the deepening interplay between CRISPR-based genome editing applications and oligonucleotide manufacturing underscores a broader industry shift toward convergent innovation.

Taken together, these dynamics signal a fundamental realignment of value creation, where technological prowess, digital fluency, and service differentiation converge to define competitive advantage. Industry participants must therefore embrace cross-disciplinary collaboration and continuous process optimization if they intend to thrive in this rapidly evolving landscape.

Assessing the Cumulative Impact of United States Tariffs in 2025 on Oligonucleotide Supply Chains Cost Structures and Market Dynamics

The imposition of new United States tariffs in 2025 has introduced a layer of complexity into global oligonucleotide supply chains. Synthesis reagents, specialized instruments, and custom service fees now carry additional duties that effectively increase procurement costs for downstream applications. In response, manufacturers and end-users have reevaluated their sourcing strategies, seeking alternatives in tariff-exempt jurisdictions and exploring regional partnerships to mitigate duty exposure.

Consequently, supply chain resilience has emerged as a focal point. Companies are diversifying their vendor base by engaging with regional producers in Europe, Asia-Pacific, and the Americas. This geographical rebalancing not only addresses tariff-related cost pressures but also reduces lead times for critical materials. At the same time, strategic inventory planning and forward-purchasing agreements have gained traction, enabling organizations to hedge against future rate adjustments.

The tariff landscape has also amplified the appeal of localized manufacturing infrastructure. Investment in domestic production facilities has accelerated, driven by incentives to avoid import levies and to align with broader reshoring initiatives. Through these investments, firms are forging deeper ties with domestic regulatory bodies and research institutions, fostering an ecosystem that prioritizes compliance, intellectual property security, and rapid innovation cycles.

As a result, stakeholders must navigate a more intricate compliance matrix, balancing cross-border trade risks against the benefits of scale and specialization. Those who proactively adapt to the new tariff regime will not only protect their margins but also unlock opportunities to forge new alliances and to exert greater control over critical supply chain nodes.

Deriving Strategic Insights from a Holistic Analysis of Oligonucleotide Market Segmentation across Product Scale Delivery Application and End-User

A nuanced understanding of market segmentation is essential for stakeholders aiming to optimize their strategic positioning. In the realm of product types, equipment and instruments continue to mature with DNA/RNA synthesizers delivering precise output for research workflows, while microarray platforms enable simultaneous synthesis of thousands of unique sequences. Reagents and consumables form another pillar, covering everything from enzymatic blends and labeling agents to purification compounds. Meanwhile, software and services have emerged as indispensable enablers, with bioinformatics suites, cloud-based management solutions, and data analysis platforms transforming raw sequence data into actionable insights. In parallel, synthesized oligonucleotides-whether DNA or RNA-fuelling applications in diagnostics, therapeutics, and beyond, underscore the centrality of high-purity end products.

Turning to synthesis scale, the dichotomy between custom protocols and large-scale manufacturing highlights differing operational imperatives. Custom providers excel at meeting bespoke sequence requirements and expedited timelines, whereas commercial-scale facilities leverage automation and volume efficiencies to serve broader therapeutic and diagnostic markets. Delivery methods further differentiate market offerings, as solid-phase synthesis remains the gold standard for reliability, while enzymatic approaches promise greener processes and reduced chemical waste.

In application contexts, diagnostics is witnessing robust adoption of oligos in biosensors, molecular imaging, and PCR-based assays, each demanding specific length, purity, and functional modifications. The drug discovery and development segment relies on lead optimization and target validation workflows to refine candidate molecules, often requiring high-throughput screening libraries. Research applications span functional genomics, gene expression analysis, and full gene synthesis, all of which depend on rapid turnaround times and consistent quality. Therapeutic avenues, such as antisense therapies, CRISPR-based interventions, and RNA interference, are driving demand for specialized chemistries and scale.

Finally, end-users encompass academic and research institutes that prioritize flexibility, contract research organizations that demand scalability and quality assurance, diagnostic laboratories that require validated reagents, and pharmaceutical and biotechnology companies that focus on regulatory compliance and large-volume deliveries. These intertwined segmentation layers illustrate the diversity of market requirements and the necessity for tailored value propositions.

Unraveling Regional Dynamics in the Oligonucleotide Synthesis Landscape across the Americas Europe Middle East Africa and Asia Pacific

Regional dynamics continue to reshape the competitive landscape of oligonucleotide synthesis. In the Americas, a combination of advanced research infrastructure, regulatory harmonization, and strong venture capital activity underpins robust innovation. From North American biotech clusters to emerging hubs in South America, organizations are increasingly investing in integrated platforms that bridge design, synthesis, and downstream applications.

Meanwhile, Europe, the Middle East, and Africa exhibit a rich tapestry of collaborative research networks. The European Union's emphasis on Horizon funding and cross-border interoperability has spurred joint ventures among academic centers and commercial entities. At the same time, Middle Eastern initiatives are focusing on biosecurity and diagnostics capacity-building, and African markets are exploring point-of-care solutions that leverage oligonucleotide-based assays for infectious disease surveillance.

Asia-Pacific has rapidly emerged as a powerhouse, driven by large-scale manufacturing capabilities, favorable government incentives, and a growing base of skilled life-science professionals. From contract manufacturers in China to innovation clusters in Singapore, regional players are capitalizing on production efficiencies and cost advantages. Simultaneously, domestic R&D investments in countries such as Japan, South Korea, and Australia are generating advanced applications in gene editing and RNA therapeutics.

As a result, each region presents distinct opportunities and challenges-ranging from intellectual property protection and regulatory alignment to talent acquisition and infrastructure development. Market participants must therefore calibrate their regional strategies to local realities, forging partnerships that leverage comparative strengths while addressing potential barriers to entry.

Highlighting Competitive Strategies and Innovator Profiles of Leading Companies Shaping the Oligonucleotide Synthesis Ecosystem

The competitive arena of oligonucleotide synthesis is defined by a spectrum of established multinational corporations, agile specialist players, and emerging biotechnology firms. Industry leaders have leveraged significant R&D budgets to enhance their instrument portfolios, broaden their reagent offerings, and integrate advanced software capabilities. These investments have enabled them to deliver end-to-end solutions that address both high-throughput screening and precision therapeutic design.

Mid-tier companies have carved out niches by focusing on high-purity custom syntheses, rapid turnaround services, and specialized chemistries. They often differentiate themselves through closer client engagement, streamlined regulatory support, and collaborative product development. Meanwhile, smaller innovators are exploring enzymatic approaches to synthesis, novel purification techniques, and AI-driven predictive analytics to challenge traditional paradigms.

Across this spectrum, partnerships and acquisitions remain a central theme. Leading instrument manufacturers have acquired bioinformatics startups to unify digital design with physical production, while reagent producers have forged alliances with academic consortia to co-develop next-generation labeling and modification reagents. Contract research organizations continue to invest in capacity expansion, anticipating growing demand for outsourced synthesis and analytical services.

Collectively, these competitive strategies underscore the importance of adaptability, cross-disciplinary collaboration, and a relentless focus on quality. Players that successfully align their R&D roadmaps with evolving customer requirements-while maintaining cost discipline and regulatory compliance-will command the greatest influence in shaping the market's trajectory.

Formulating Actionable Recommendations to Propel Innovation Collaboration and Resilience within the Oligonucleotide Industry for Sustained Growth

To maintain a leadership position, industry stakeholders should prioritize collaborative innovation across the synthesis value chain. Establishing open innovation partnerships between instrument makers, reagent suppliers, and end-users can accelerate the translation of laboratory breakthroughs into scalable processes. In doing so, companies can pool resources, share risk, and co-create solutions tailored to emerging applications such as RNA therapeutics and point-of-care diagnostics.

Furthermore, investing in digital ecosystems will enhance operational agility. By integrating predictive analytics, real-time monitoring, and cloud-based design tools, organizations can optimize yield, reduce production bottlenecks, and respond rapidly to shifts in demand. These digital levers should be complemented by robust quality management systems that adhere to evolving regulatory expectations in key markets.

Diversification of manufacturing footprints is equally critical. Leaders should evaluate strategic site expansions in tariff-exempt regions and develop contingency plans for potential trade disruptions. Such geographic flexibility not only mitigates cost volatility but also supports localized service delivery, strengthening customer relationships and supply chain resilience.

Finally, workforce development must remain a top priority. Cultivating a talent pool with expertise in synthetic biology, bioinformatics, and regulatory science will equip companies to navigate complex technical challenges. By fostering a culture of continuous learning and cross-functional collaboration, organizations can drive sustained innovation, minimize time to market, and secure competitive differentiation.

Detailing Rigorous Research Methodology Combining Primary Engagements and Secondary Analyses to Ensure Robust Insights in Oligonucleotide Studies

This analysis is grounded in a comprehensive research framework combining primary engagements with subject-matter experts and secondary data analyses from peer-reviewed journals, patent databases, and regulatory publications. Primary research included in-depth interviews with senior executives, R&D directors, and supply chain managers across major instrument manufacturers, reagent producers, contract research organizations, and end-user institutions.

Secondary research involved a systematic review of scientific literature, technical white papers, and conference proceedings, supplemented by data from public filings and government reports. Patent landscaping exercises were conducted to identify emerging technological trends and competitive positioning. Additionally, regulatory databases were mined to track recent approvals, guidelines, and compliance developments affecting synthesis processes.

Data triangulation was employed to validate insights, cross-referencing qualitative interview findings with quantitative performance metrics where available. Analytical techniques such as SWOT assessments, value chain mapping, and scenario planning underpinned the study's strategic conclusions. Peer reviews from external advisors and iterative feedback loops with industry participants further enhanced the robustness and relevance of the final deliverable.

This rigorous methodology ensures that the report's insights reflect both the current state of the market and forward-looking perspectives, equipping stakeholders with a reliable foundation for strategic decision-making.

The oligonucleotide synthesis market is characterized by rapid technological advances, evolving regulatory landscapes, and shifting trade dynamics. From the integration of cloud-based bioinformatics to the pursuit of greener enzymatic synthesis routes, the sector is poised for both incremental and disruptive change. Regional variations, particularly in the Americas, EMEA, and Asia-Pacific, underscore the necessity for tailored strategies that address local regulatory, economic, and infrastructural realities.

Segmentation analysis reveals that differentiated value propositions-in instrumentation, reagent portfolios, software capabilities, and service models-will drive future competitiveness. End-user demands for precision, speed, and cost-effectiveness continue to accelerate adoption across diagnostics, drug discovery, research, and therapeutic development.

Looking ahead, the firms that excel will be those that seamlessly integrate digital and physical workflows, diversify their geographic footprints, and cultivate deep partnerships across the value chain. Investment in workforce development, sustainable processes, and adaptive quality systems will serve as key enablers of growth.

Ultimately, a strategic focus on collaborative innovation, supply chain resilience, and regulatory foresight will define the next chapter of oligonucleotide synthesis. Organizations that embrace these imperatives will be best positioned to transform scientific potential into tangible solutions that address critical healthcare and research challenges.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oligonucleotide Synthesis Market, by Product Type

  • 8.1. Equipment/Instruments
    • 8.1.1. DNA/RNA Synthesizers
    • 8.1.2. Microarray Synthesizers
  • 8.2. Reagents & Consumables
    • 8.2.1. Enzymes
    • 8.2.2. Labeling Reagents
    • 8.2.3. Purification Reagents
    • 8.2.4. Synthesis Reagents
  • 8.3. Software & Services
    • 8.3.1. Bioinformatics Tools
    • 8.3.2. Cloud Storage & Management Solution
    • 8.3.3. Custom Oligo Synthesis Services
    • 8.3.4. Data Analysis Platforms
  • 8.4. Synthesized Oligonucleotides
    • 8.4.1. DNA Oligonucleotides
    • 8.4.2. RNA Oligonucleotides

9. Oligonucleotide Synthesis Market, by Synthesis Scale

  • 9.1. Custom Oligonucleotide Synthesis
  • 9.2. Large-Scale/Commercial Manufacturing

10. Oligonucleotide Synthesis Market, by Delivery Method

  • 10.1. Enzymatic Synthesis
  • 10.2. Solid-Phase Synthesis

11. Oligonucleotide Synthesis Market, by Application

  • 11.1. Diagnostics
    • 11.1.1. Biosensors
    • 11.1.2. Molecular Imaging
    • 11.1.3. PCR & Sequencing
  • 11.2. Drug Discovery & Development
    • 11.2.1. Lead Optimization
    • 11.2.2. Target Validation
  • 11.3. Research
    • 11.3.1. Functional Genomics
    • 11.3.2. Gene Expression Analysis
    • 11.3.3. Gene Synthesis
  • 11.4. Therapeutics
    • 11.4.1. Antisense Therapy
    • 11.4.2. CRISPR-Based Therapeutics
    • 11.4.3. RNA Interference

12. Oligonucleotide Synthesis Market, by End-User

  • 12.1. Academic & Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Diagnostic Laboratories
  • 12.4. Pharmaceutical & Biotechnology Companies

13. Oligonucleotide Synthesis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oligonucleotide Synthesis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oligonucleotide Synthesis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oligonucleotide Synthesis Market

17. China Oligonucleotide Synthesis Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. Ajinomoto Bio-Pharma Services
  • 18.7. Bio-synthesis Inc.
  • 18.8. Biocomma Ltd.
  • 18.9. Biolegio B.V.
  • 18.10. Biolytic Lab Performance Inc.
  • 18.11. Bon Opus Biosciences, LLC
  • 18.12. Creative Biogene
  • 18.13. Cusabio Technology LLC
  • 18.14. Danaher Corporation
  • 18.15. Eurofins Genomics LLC
  • 18.16. Eurogentec S.A. by Kaneka Corporation
  • 18.17. GE HealthCare Technologies Inc.
  • 18.18. Generi Biotech
  • 18.19. Genscript Corporation
  • 18.20. Hongene Biotech Corp.
  • 18.21. LGC Genomics Limited
  • 18.22. Maravai Intermediate Holdings, LLC
  • 18.23. Merck KGaA
  • 18.24. Microsynth AG
  • 18.25. Nitto Denko Avecia Inc.
  • 18.26. Novartis AG
  • 18.27. parent added
  • 18.28. PerkinElmer, Inc.
  • 18.29. REPROCELL Inc.
  • 18.30. Synbio Technologies
  • 18.31. TAG Copenhagen A/S
  • 18.32. TCI Chemicals (India) Pvt. Ltd.
  • 18.33. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DNA/RNA SYNTHESIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DNA/RNA SYNTHESIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DNA/RNA SYNTHESIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY MICROARRAY SYNTHESIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY MICROARRAY SYNTHESIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY MICROARRAY SYNTHESIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LABELING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LABELING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LABELING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PURIFICATION REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PURIFICATION REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PURIFICATION REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CLOUD STORAGE & MANAGEMENT SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CLOUD STORAGE & MANAGEMENT SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CLOUD STORAGE & MANAGEMENT SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CUSTOM OLIGO SYNTHESIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CUSTOM OLIGO SYNTHESIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CUSTOM OLIGO SYNTHESIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DNA OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DNA OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DNA OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RNA OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RNA OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RNA OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CUSTOM OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CUSTOM OLIGONUCLEOTIDE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CUSTOM OLIGONUCLEOTIDE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LARGE-SCALE/COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LARGE-SCALE/COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LARGE-SCALE/COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY BIOSENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY MOLECULAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY MOLECULAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PCR & SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PCR & SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PCR & SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY FUNCTIONAL GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY FUNCTIONAL GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GENE EXPRESSION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ANTISENSE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ANTISENSE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ANTISENSE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CRISPR-BASED THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CRISPR-BASED THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CRISPR-BASED THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RNA INTERFERENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RNA INTERFERENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 260. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 263. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 264. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 266. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 267. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 268. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 270. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 271. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 272. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 273. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY D